New Business Models for Sustainable Antibiotics

Kevin Outterson

January 2014

Working Group on Antimicrobial Resistance: Paper 1
ABOUT THE AUTHOR

Kevin Outterson (mko@bu.edu) is a Professor at the Boston University School of Law, where he co-directs the Health Law Program. He is a member of the antimicrobial resistance working group at the US Centers for Disease Control and Prevention. He blogs US health care policy at The Incidental Economist. His academic papers are collected at http://ssrn.com/author=340746 and at Google Scholar.

ACKNOWLEDGEMENTS

An earlier version of this paper was written as background for a roundtable meeting held at Chatham House on 2 October 2013 on the subject of “Aligning Incentives for Antibiotic Development and Use with Public Health Needs”.¹

Financial support was received from the Boston University School of Law the University of Iowa College of Law.

Any views expressed are my responsibility alone.

Executive Summary

Antibiotics are powerful drugs that prevent many deaths each year. Modern medicine relies on antibiotics as a safety net. Many invasive medical procedures would be much more dangerous without effective antibiotics. Global trade, travel and security would be threatened by a resurgence of untreatable infectious diseases. Antibiotics are precious global resources that must be managed on a sustainable ecological basis, akin to fisheries.

But today, antibiotics are mismanaged in a haphazard fashion. Antibiotics are uniquely vulnerable to premature destruction through resistance. Physicians, hospitals, drug companies, payers, patients, and food producers often face perverse financial incentives that encourage inappropriate use of these drugs and undercut incentives to create new ones. Many stakeholders believe that an antibiotic crisis is fast approaching or may already be upon us. Due to the long lead times for antibiotic R&D, society needs to act a decade before the need becomes immediately urgent.

Therefore an important task is to fix these broken economic incentives. Any solution must overcome three obstacles simultaneously: (1) inadequate market incentives for companies to invest in antibiotic R&D; (2) inadequate market incentive to protect these valuable resources from overuse and premature resistance; and (3) inadequate market incentives to ensure global access to life-saving antibiotics. Creating new drugs will achieve no lasting success if the underlying incentives for inappropriate use are not addressed, or if the drugs do not reach patients in need.

Antibiotic delinkage may offer the most promising avenue for a sustainable approach. Delinkage recognizes that rewarding antibiotic producers and sellers based on volume is fundamentally inappropriate. This paper explores all of the antibiotic delinkage models in the existing literature, bringing some order to a variety of proposals.

Introduction

Experts are raising alarms about a possible return to the pre-antibiotic era, and are beginning to describe comprehensive solutions.\(^2\)

---

Resistance is an evolutionary response to antibiotic use, so many policy options focus on keeping slightly ahead of evolution through faster introduction of new antibiotics, a kind of arms race between drugs and bugs. This evolutionary and competitive perspective is a dominant paradigm.

This paper also employs a complementary framework, based in ecology. The ecological paradigm treats antibiotic effectiveness as a precious common pool resource, akin to fisheries or any other exhaustible resource. Long-term management of common pool resources requires coordination and balance between conservation and generation of new products. It also explores the complex ecological and epidemiological systems wherein resistance spreads. The ecological paradigm has emerged as an important approach amongst those who study resistance.

Under both paradigms, experts often look to law and economics to solve incentive problems for antibiotics. Economic incentives provided by the patent system have driven commercial drug R&D and innovation, with a good deal of success in wealthy countries. If new knowledge and technologies were freely available, and capable of being copied by others, the incentive for private actors to invest in their development would be very weak. Patent law seeks to solve this problem with a period of exclusivity, effectively turning knowledge into property for a limited time.

---


4 Global Risks 2013, at 28 (“While viruses may capture more headlines, arguably the greatest risk of hubris to human health comes in the form of antibiotic resistant bacteria. We live in a bacterial world where we will never be able to stay ahead of the mutation curve. A test of our resilience is how far behind the curve we allow ourselves to fall.”).


7 The patent system works best for diseases that afflict wealthy populations, but is much less effective for conditions endemic in poorer populations. WHO, Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination, (Geneva: Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination, 2012). Patents have also not driven the required levels of innovation for conservation measures such as infection control, point of care diagnostics and antibiotic stewardship.
Unlike physical goods or land, knowledge can be shared without diminishing the original source.\(^8\) This characteristic (known as “nonrivalry”) is a key means by which unrestricted knowledge benefits society. But it is weakened in the case of antibiotics due to resistance.\(^9\) Each dose potentially diminishes the effectiveness of the next, effectively destroying the usefulness of both the knowledge and the resulting product (rivalry). The fundamental reworking of patent law theory to account for this fact and to design alternative means to meet the same end are underway, most prominently in the concept of antibiotic delinkage.

**Figure 1. Nonrivalry and rivalry in pharmaceuticals.**

Under traditional “linkage,” sales volumes and price determine the return on investment for a drug. Due to resistance, maximizing sales volumes of antibiotics is not in the interest of global public health. Delinkage removes the link between the funding of antibiotic R&D and sales volumes. Under delinkage, companies will be paid for antibiotic R&D and innovation on some other basis, as described below. Delinkage seeks to solve three problems simultaneously: (1) inadequate market incentives for companies to invest in antibiotic R&D; (2) inadequate market incentive to protect these valuable resources from overuse and premature resistance; and (3) inadequate market incentives to ensure global access to life-saving antibiotics.\(^10\)

---

\(^8\) Thomas Jefferson described nonrivalry to support the intellectual property clause in the US Constitution: “Its peculiar character [of an idea], too, is that no one possesses the less, because every other possesses the whole of it. He who receives an idea from me, receives instruction himself without lessening mine; as he who lights his taper at mine, receives light without darkening me.” Thomas Jefferson to Isaac McPherson, 13 Aug. 1813. *Writings of Thomas Jefferson* 13:333-335.


\(^10\) Beyond antibiotics, delinkage is primarily proposed as a tool to ensure access to drugs by low- and middle-income populations and to incentivize R&D into neglected diseases. In these situations, nonrivalry is not an issue absent resistance.
The general concept of antibiotic delinkage has been broadly endorsed by industry stakeholders, including EFPIA, Sir Andrew Witty and David Payne at GlaxoSmithKline, John Rex at AstraZeneca, and some US-based executives including Daniel Burgess at Rempex Pharmaceuticals. The Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the EFPIA, has announced a call for proposals to create a “new business model for antibiotic development.” Antibiotic delinkage was also a significant topic at a single day Brookings Council on Antibacterial Drug Development (BCADD) workshop co-sponsored by the FDA and the Brookings Institute in February 2013 and a separate workshop sponsored by the Pew Charitable Trusts in January 2013. Beyond antibiotics, key international organizations and civil society groups have endorsed other delinkage proposals as a solution to pharmaceutical access and innovation problems generally, including the WHO Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG), the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG), the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, the UN Human Rights Council, Médecins Sans Frontières, and Knowledge Ecology International.

This paper is designed to foster discussion by describing antibiotic delinkage models in more detail, including revisiting some fundamental assumptions in the conventional wisdom relating to antibiotics. While resistance affects antibiotics, antivirals, antiretrovirals and

11 Richard Bergström, Development of new antibiotics – the industry perspective (Uppsala: ReACT, 2011).
13 Ibid.
14 Other senior executives were supportive at the BCADD Brookings/FDA meeting in February 2013 and in conversations not for attribution.
15 Innovative Medicines Initiative, IMI 9th Call For Proposals: New Drugs for Bad Bugs (ND4BB), 2013.
21 UN Human Rights Council, Access to medicines in the context of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, A/HRC/23/L.10/Rev.1 (June 2013).
antifungal agents, this paper focuses primarily on antibiotics. Resistance is certainly a global problem, but this paper focuses primarily on the EU and US as leading research centres for antibiotic development and major markets for these products.

This paper first considers three key imperatives in order to frame discussion:

- Understand the multi-disciplinary nature of the problem,
- Focus on key pathogens, and
- Challenge conventional wisdom.

In the second part, this paper explores the antibiotic delinkage models described in the current literature.

**Part I: Key imperatives**

**A. Understand the multi-disciplinary nature of the problem.**

Drug resistance leading to clinical failure is studied by professionals from many disciplines, including infectious disease physicians, evolutionary biologists, economists, epidemiologists, public health experts, and researchers who study resistance from agricultural use. It is a mistake to focus excessively on any one of these disciplinary perspectives to the exclusion of a broader view:

- To a physician, the problem is a sick or dying patient and the solution is access to effective drugs as soon as possible, avoiding the chance that life would be threatened by failure to prescribe in the absence of definitive diagnosis.

- To an economist, the lack of new antibiotic drugs and insufficient investment in conservation are primarily questions of economic incentives in the market, and the solution is to adjust the expected net present value for companies making the decision to invest and to incentivize clinicians and other stakeholders to avoid clinically unnecessary use of antibiotics.

- From an evolutionary perspective, the problem is inappropriate use that leads to premature resistance. The solutions are conservation measures limiting antibiotic use through hospital formularies, improved diagnostics, community clinical guidelines, and reducing antibiotic use in agriculture.

- From an ecological perspective, the problem is people becoming sick with avoidable infections. The solutions are better public health, preventative vaccines, and more effective infection control, especially in health care settings, to reduce the force of infection and thereby hinder the spread of both resistant and non-resistant strains.

These perspectives can be integrated by considering them sequentially as in Figure 2.
Seen in this light, clinical failure is not just an economic problem arising from inadequate market incentives, but also reflects a prior evolutionary failure to conserve a precious resource and the initial ecological failure to prevent infection. Each step is an important part of the chain of events leading to clinical failure and therefore a focus for policy intervention. The ultimate goal is to prevent untreatable infections, not just to introduce more drugs.

In the US and the EU, each step also involves different stakeholders and regulators, leading to a lack of coordination across the entire process. Effective coordination is key to preserving common pool resources such as fisheries or antibiotics.

We should also note some of the positive and negative interactions between these four stages:

- **Successful Stage 1 infection control** reduces the number of patients needing treatment, which reinforces success by delaying Stage 2 resistance and Stage 4 clinical failure. Stewardship, conservation, public health, and infection control delay resistance and save lives.

- **Successful Stage 1 and 2 measures** directly undermine Stage 3 economic incentives to create new drugs by reducing the number of customers. Stewardship, conservation, public health, and infection control diminish both demand and the need for new drugs in the pipeline.  

- **Successful Stage 3 incentives** that provide revenue based on sales volumes directly conflict with Stage 2 stewardship and conservation measures and possibly Stage 1 infection control and public health as well. This is a key problem with the present system of antibiotic linkage.

- **R&D should not be thought of as exclusively an input for Stage 3 drugs.** R&D is also vitally important for Stage 1 technologies such as vaccines and other technologies

---


25 Ibid.
necessary for infection control and public health, as well as Stage 2 technologies such as better diagnostics and effective conservation programs. Economic analysis of the incentives for Stage 1 and 2 technologies is warranted to the same degree as Stage 3, but is less common.

These insights should significantly influence the design of solutions: any antibiotic business model must simultaneously reinforce efforts in prevention, conservation, new drugs, and clinical success, while preserving and enhancing access to these life-saving drugs to all patients who need them.

B. Focus on key pathogens.

Many people are infected with self-resolving conditions that may not warrant antibiotic drugs. Others are hospitalized with serious or life-threatening infections. For some of these hospitalized patients, infectious disease physicians have no effective treatment options available due to resistance. The current number of such patients is significant and increasing, and may increase dramatically through ecological and evolutionary changes.

For our purposes, infections fall into three categories. The first category includes emerging infectious diseases for which we have never possessed effective treatment options. The second category includes pathogens that are currently treatable, but may transition in the future to be untreated due to resistance. The third category is clinical failure, including well-known infectious diseases that previously were susceptible to treatment, but are now untreated after evolutionary adaptation leading to multi-drug resistance.

These three categories represent different types of problems, with potentially divergent policy options and solutions. This paper will focus primarily on the transitions between Categories 2 and 3 for bacterial infections. Given scarce resources, our efforts should be prioritized appropriately, as the CDC recognized in its recent report, Antibiotic Resistance Threats in the United States, 2013.

To the extent possible, our priorities should be:

- **Serious or life-threatening infectious diseases.** Self-resolving bacterial diseases and other infections that are not serious or life threatening have clinical significance, but do not warrant urgent action.

- **Untreatable pathogens.** Resistance is not an absolute concept - in most cases resistance is a progressive loss of susceptibility with breakpoints that over time reduce clinical effectiveness. Resistance varies by bug-drug pairing and may also vary by body site. Resistance to one drug (say, methicillin) is not clinically relevant if other safe and effective treatments are available. Virtually every pathogen exhibits some resistance to some treatment. Some pathogens harbour resistance even

---

27 Ibid.
before a new drug is released. Others are still fully effective against some pathogens despite decades of use. For example, Group B *Streptococci* remain fully susceptible to penicillin after seven decades. In short, the fact that some resistance has been documented does not imply that the condition is untreatable or that the drug is useless. The most salient current threats to public health come from Category 3 serious infectious diseases that are currently untreatable, leading to clinical failure.

- **Time horizon.** Due to the long lead-time for antibiotic drug R&D, we must also be concerned about Category 2 infections that might plausibly transition to untreatable Category 3 infections during the time horizon. These transitions are key events as illustrated in Figure 3.

**Figure 3. Transitions between pathogen categories.**

![Diagram](image)

The transition from Category 1 to 2 can take perhaps 10-15 years through R&D. Prevention also plays a key role reducing the human health impact of an untreatable disease. The transition from Category 2 to 3 will vary by drug-bug combination and many other factors accelerating or delaying resistance. For example, inappropriate use and poor prevention may accelerate resistance while conservation and infection control may delay it. We lack good empirical estimates of the actual likelihood of these events over various time frames for most drug-bug pairs. R&D can also push an untreatable pathogen from Category 3 back to Category 2 through the discovery of a novel treatment, again with a long time lag. To the extent that any pathogen is likely to become a significant burden to human health, R&D and prevention programs must begin with sufficient lead-time before the transition from Category 2 to 3.

**C. Challenge conventional wisdom.**

The first-order goal is to combat resistance by exploring new business models. In order to do that effectively, conventional wisdom must occasionally be challenged. The following examples of conventional wisdom share a common focus on Stage 3: bringing new drugs to the market. If the sole goal were more new drugs, this focus would be appropriate. But as Figure 2 makes clear, the goal is preventing clinical failure and we have additional policy levers that should be considered in conjunction with new antibiotics. Five examples of conventional wisdom are challenged:

- A large number of antibiotics should be approved in the next decade;
- A large number of *high quality* antibiotics should be approved in the next decade;
- Antibiotic clinical trials should be simplified;
• Billions of dollars should be spent over the next decade to bring more antibiotics to the market; and
• Antibiotics are unprofitable due to a short course of treatment.

Conventional Wisdom 1: A large number of antibiotics should be approved in the next decade. The number of new molecular entity (NME) antibiotics has fallen over the past 30 years. But simple numerical counts obscure the question of clinical impact. Of the 61 NME systemic antibiotics approved by the FDA from 1980-2009, a decreasing number qualified for priority review.\(^{28}\) Priority review is given to drugs that are expected to treat serious conditions and provide significant improvements in safety or efficacy over existing therapies.\(^{29}\) As a class, antibiotics also suffered from market withdrawals at more than triple the rate of other drugs (42.6\%, a total of 26 out of 61 antibiotics).\(^{30}\) Many of these withdrawn antibiotics were follow-on cephalosporins (n=10) and fluoroquinolones (n=9) that did not come to the market with clear competitive advantages in terms of enhanced efficacy and safety profiles.\(^{31}\) Six were withdrawn for safety-related reasons.\(^{32}\) It does not appear that resistance played a significant role in these withdrawals, as other antibiotics with similar mechanisms of action and resistance profiles remained on the market.\(^{33}\) Incentives must focus on high quality antibiotics that treat serious conditions with improved safety or efficacy.\(^{34}\) A small number of outstanding new antibiotics would be a much better outcome than a large number of undifferentiated antibiotics without enhanced efficacy and safety in serious or life-threatening conditions. Rewards should be concentrated on the best drugs and unnecessary drivers of resistance should be minimized.

Careful attention to incentive design is important here. In the recently enacted GAIN Act in the US, a reward of an additional five years of exclusivity is available to “qualified infectious disease products.” The definition of qualified infectious disease product weakens the standard for priority review by dropping the requirement of significantly improved safety or efficacy. The GAIN Act therefore fails to focus the incentive exclusively on the highest quality antibiotics and antifungals. If the GAIN Act triggers a large number of new antibiotic introductions, it might unfortunately lead to greater evolutionary pressures and therefore resistance.

\(^{30}\) Outterson, ‘Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009,’ Op. Cit. n. 28. Some of these antibiotics were withdrawn for safety reasons, but the larger number were simply withdrawn by the companies due to disappointing sales, lack of competitive safety and efficacy profiles, or unknown reasons.
\(^{31}\) Ibid.
\(^{32}\) Ibid.
\(^{33}\) Ibid.
\(^{34}\) Outterson K, Powers JH, Gould IM, Kesselheim AS, ‘Questions About the 10 x ’20 Initiative,’ Clinical Infectious Diseases, 2010;51:751-752.
At the Chatham House Roundtable in October 2013, some participants suggested that it is difficult to predict how R&D programs will unfold over time, which might lead to more (or fewer) market introductions than expected. While this is undoubtedly true, the point being pressed here is whether incentives should be designed to result in a specific number of market introductions. From a societal point of view, the objective is an optimal number of introductions, not a fixed target such as the “10 by 2020” goal articulated by the Infectious Diseases Society of America (IDSA).

Conventional Wisdom 2: A large number of high quality antibiotics should be approved in the next decade. Assume that targeted incentives were highly successful and the EMA and the FDA approve 10 high quality antibiotics in the next decade. It is understandable that infectious disease physicians eagerly desire many more weapons against pathogens. But would that be the best outcome from a long-term public policy perspective? If the drug class were statins, or cancer drugs, or indeed any other class, the answer would be an unequivocal yes, so long as the new drugs represented an improvement over existing therapies. If better cardiovascular or cancer drugs could be created and sold at affordable prices, society would be clearly better off with immediate access today.

The same may not be true for antibiotics. Introducing 10 high-quality novel antibiotics in one decade will jump start the evolutionary process of resistance for all of them. If antibiotic innovation was easy, then this would provide flexible treatment options and any antibiotics destroyed through resistance could be replaced in due course. But the evidence of the past three decades suggests a declining return on antibiotic R&D, making new products harder to discover. If antibiotic innovation is increasingly difficult and expensive, then the best long-term policy would space out the introduction of valuable molecules over time. Rather than have 10 antibiotics enter the market simultaneously, it may be more appropriate for society to generate only a few high-quality antibiotics per decade, based on clinical need as resistance progressed. Unfortunately, the current incentive framework does not permit this option. The companies hold a time-limited property right that expires with the last patent or exclusivity period. They cannot afford to let a truly remarkable product sit on the shelf while the patent clock ticks. One potential delinkage solution to this particular problem is the Strategic Antibiotic Reserve, discussed below.

Some roundtable participants noted that follow-on antibiotics are sometimes superior to the first-in-class molecule in terms of safety and effectiveness, building on the lessons learned from the pioneers. This process of incremental innovation is undoubtedly valuable, but it illustrates a key problem in the market for antibiotics. Rewards should be greatest for precisely these best-in-class drugs, delivering a very significant financial reward to the company. But the continued presence of the lesser drugs is problematic for two reasons. First, the company marketing the lesser drug has every reason to deploy Phase IV studies and marketing to gain sales, to the detriment of the better innovation. Second, sales of the lesser drugs may trigger resistance in the best-in-class drug. In short, society needs

---

incremental innovation, but must focus rewards on the higher quality antibiotics, while protecting those drugs from competition from other drugs in their class or functional resistance group.

Finally, the evolutionary perspective should give us pause before we attempt to bring more antibiotics to market without strong controls on use, which may be the equivalent of throwing more fuel on the evolutionary fire. As Dennis Maki famously put it at an IDSA meeting:

“The development of new antibiotics without having mechanisms to insure their appropriate use is much like supplying your alcoholic patients with a finer brandy.”

Conventional Wisdom 3: Antibiotic clinical trials should be simplified. The expected net present value of antibiotic R&D investments will improve if the time to approval is shortened (reducing the number of years over which the investments are discounted) and by reducing the actual costs of the trials (by reducing their number, size and complexity). One recent proposal in Europe to simplify antibiotic clinical trials is the flexible regulatory framework proposed by John Rex et al. in Lancet Infectious Diseases. A somewhat similar approach in the US is the Limited Population Antibacterial Drug (LPAD) proposal supported by the IDSA. These efforts are likely to lead to antibiotics being approved more quickly, but as discussed above, we do not know yet whether that would be a good thing for society. If these new antibiotics are approved based on more limited efficacy and safety data, then we might be just accelerating resistance by introducing new antibiotics with limited clinical utility or greater safety problems that generate cross-resistance to better drugs. We cannot know a priori whether these clinical trial initiatives will improve health without much better post-marketing surveillance data on resistance, safety, and effectiveness.

Conventional Wisdom 4: Billions of dollars should be spent over the next decade to bring more antibiotics to the market. It would be prudent to consider the alternative interventions described on Figure 2 before deciding whether this might be a wise investment of public funds. The goal is to prevent clinical failure, not just to approve more drugs. If so, before billions are spent to bring more antibiotics to market, perhaps we should evaluate alternative investments to prevent clinical failure, such as novel vaccines, public health measures, better hospital infection control, better diagnostics, improved conservation, and other ecological, epidemiological and evolutionary interventions. For example, hospitals in the US bill for treating infections, but are almost never paid for preventing them. Reimbursement systems in Europe and the US are increasingly seen as

38 Eastern Research Group Study for HHS/FDA (pending, 2014).
policy levers for reducing healthcare associated infections. The empirical record is exceedingly thin on the comparative cost-effectiveness of additional investments in new antibiotics versus investment of the same resources in other options.

Some roundtable participants noted that in the developing world, antibiotics are frequently underutilized, leading to many unnecessary deaths. For these populations, resistance is a remote threat while bacterial diseases are omnipresent and highly dangerous. It was also noted that antibiotics are needed in these countries partially due to significant weaknesses in public health infrastructure such as clean water and food sanitation. For these reasons, in developing countries, scarce financial resources might well be better spent in improving public health and appropriate access to antibiotics.

**Conventional Wisdom 5: Antibiotics are unprofitable due to a short course of treatment.** Antibiotics may well be currently unprofitable for drug companies, but the principal reason is most certainly not the short course of treatment. Oncology drugs are also prescribed for short courses of treatment, but feature astounding prices that contribute to a powerful incentive for investment in a difficult area of R&D. In such an environment, it is unsurprising that the number of oncology drugs approved has risen remarkably over the past three decades. They have at least three features that may explain their pricing success: (1) patients with life-threatening conditions, (2) an absence of competitive (substitutable) generic drugs, and (3) a reimbursement system (at least in the US Medicare Part B) that encourages physicians to choose the higher priced drug.

For antibiotics, the second and third elements are missing. New antibiotics often are forced to compete with generic antibiotics that remain effective. Empiric therapy proceeds while awaiting diagnostics, making it more difficult for a company to differentiate their products from low-cost generics like vancomycin. In addition, the reimbursement system for antibiotics is less favorable. In the US and some European countries, hospital antibiotics are generally included in the bundled rate for the admissions (like the diagnosis-related groups - DRGs), giving the hospital strong incentives to choose the lower-cost antibiotic where clinically appropriate. Weak antibiotic profits are principally a product of the pricing regime and generic competition, not the short course of treatment.

Weak profits for antibiotics are surprising and disturbing, given the tremendous social value of these drugs. Estimates suggest that the social value of antibiotics greatly exceed the market price. Put another way, antibiotics are highly valuable from society’s perspective, but given little private value in the market. This gap between private and social value is a significant problem and opportunity. Delinkage could significantly increase overall antibiotic

---

revenues for drug companies and still remain an excellent social bargain. We now turn to antibiotic delinkage models.

Part II: Antibiotic delinkage models.

A. The traditional business model for pharmaceuticals – here described as linkage – does not work well for antibiotics.

The prevailing business model is to recover pharmaceutical R&D investments through sales revenues above marginal cost during a period of patent-based exclusivity. For antibiotics, at least three aspects of this traditional business model are unhelpful. First, it may encourage firms to market their drugs aggressively during the exclusivity period and in particular when patent expiration looms, driving resistance through overuse and misuse. Net revenues are driven by unit sales since the ability to raise unit prices on antibiotics in the US and Europe is somewhat limited. After patent expiration, the model encourages multiple generic entries and price competition, which has also been linked to resistance. This standard linkage model therefore encourages the development of resistance by driving unit sales.

The second negative aspect of linkage relates to conservation methods. Any successful Stage 1 prevention or Stage 2 conservation effort directly reduces the demand for antibiotic products from pharmaceutical companies and therefore the incentive for Stage 3 new drug R&D. For example, vaccination with the pneumococcal conjugate vaccine (PCV7) reduced the incidence of invasive pneumococcal disease in the US, cases which otherwise might have resulted in antibiotic use. Ideally, all strategies in Figure 2 would work together to prevent clinical failure, but the traditional linkage model puts Stage 3 new drug R&D at odds with the previous stages, with disruptive effects.

The third difficulty is rooted in the market for antibiotics, particularly the relatively low prices. Much has been written about resistance destroying drugs, but in actual antibiotic markets, many generics remain highly effective for decades, at least for the majority of patients, and exert strong downward pricing pressure on new antibiotics. This pricing pressure is considerable. One example is the treatment of Clostridium difficile, a severe intestinal infection identified by the CDC as one of three “urgent threats” in the United States.

---

44 While theory suggests the “patent waste” hypothesis is true, empirical confirmation is needed. In the final years of exclusivity, companies may scale back on marketing, to prevent spillovers to imminent generic competition. See Outterson, ‘The Legal Ecology of Resistance: The Role of Antibiotic Resistance in Pharmaceutical Innovation,’ Op. Cit. n. 24.


46 It is certainly true that any successful health promotion reduces demand for pharmaceuticals, but the companies have identified conservation and other restrictions on sales as uniquely difficult for antibiotics.


48 Projan, ‘Why is Big Pharma Getting Out of Antibacterial Drug Discovery?,’ Op. Cit. n. 2. The markets for antivirals and antiretrovirals are quite different.
Fidaxomicin (Dificid) is a recently introduced drug to treat *C. difficile*, but it must compete against two existing drugs, generic metronidazole and oral vancomycin (generic if compounded for the hospital and also available as a branded oral drug). In a recent economic model, fidaxomicin was not cost effective when compared to the existing pricing of metronidazole and vancomycin. So long as generic antibiotics retain clinical effectiveness, companies struggle to gain significant pricing premiums for new drugs. These pricing conditions diminish incentives to bring new antibiotics to market. Ironically, this might be the correct market response from a societal point of view, slowing down new drug introductions when immediate clinical need is low. But given the long time lags between investment and drug introduction, if companies dismantle their antibiotic research enterprise, it may be difficult to reassemble the human capital and research infrastructure in time to respond. Along the same lines, we need second- and third-line treatment options that are held in reserve until first-line treatments fail.

**B. Applying delinkage concepts to various proposals for antibiotic incentives.**

1. **Antibiotic delinkage models.**

Under delinkage, companies will no longer be paid according to antibiotic sales volumes, which necessitates another source of revenue. From the companies’ perspective, the primary objective is significantly increased total revenue streams for antibiotics with reduced commercial risks. From a social perspective, the overriding goal is related, but distinct: preventing clinical failure from untreatable infections. Delinkage models must achieve multiple objectives simultaneously: encouraging disease prevention and control, conservation of antibiotics, new production, and access when needed. Solutions must be sustainable over very long time horizons.

A large number of incentives are presently being discussed relating to antibiotics, but they are not delinkage models unless the company is no longer paid on the basis of sales volume. Delinkage requires an entirely new business model. Antibiotic delinkage has several key components:

- Delink revenues from sales volume;

---

52 Push and pull incentives that are not delinkage include Advance Market Commitments (AMCs), Priority Review Vouchers (PRVs), Limited Population Antibacterial Drug (LPAD) approval, tiered regulatory frameworks, tax credits, fast-tracking, streamlining clinical trials, direct funding of R&D, orphan drug designation, the GAIN Act, the IMI, and Project BioShield. For a comprehensive review, see Mossialos E, Morel CM, *Policies and Incentives for Promoting Innovation in Antibiotic Research*, (London: LSE/WHO, 2010), [http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf](http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf)
• Increase total company revenues for antibiotics;\textsuperscript{54}
• Encourage long-term drug-bug coordination by stakeholders;\textsuperscript{55} and
• Preserve and enhance access without regard to ability to pay.\textsuperscript{56}

Delinkage may also include these features:

• Condition some payments on conservation targets (described below as “delinkage plus”); and
• Provide additional revenue streams for prevention, conservation and access in low-income populations, which are chronically underfunded in current systems, without sustainable business models.

As part of the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property,\textsuperscript{57} the WHO regions solicited proposals on health R&D that included significant delinkage elements as one of three primary assessment criteria.\textsuperscript{58} The WHO regional offices shortlisted 24 proposals for consideration,\textsuperscript{59} including four of particular importance to antibacterial resistance. The four are:

• Antibiotics Innovation Funding Mechanism (AIFM);\textsuperscript{60}
• Building a Diagnostic Innovation Platform to Address Antibiotic Resistance (Dx Platform),\textsuperscript{61}
• Establishing a Drug Discovery Platform for Sourcing Novel Classes of Antibiotics as Public Goods (Public Goods);\textsuperscript{62} and
• Multiplexed Point-of-Care Test for Acute Febrile Illness (AFI Dx).\textsuperscript{63}

\textsuperscript{54} Assuming the sector suffers from underinvestment.
\textsuperscript{55} Coordination is a key unmet need currently. Ideally, the new business model for antibiotics will include a strong coordination mechanism.
\textsuperscript{56} Global deaths from treatable bacterial infections are much larger than current deaths from resistant bacterial infections. Global health would dramatically benefit if access to existing antibiotics were expanded to all appropriate life-saving clinical opportunities.
\textsuperscript{57} Available at \url{http://www.who.int/phi/implementation/antibiotics_innovation_funding_mechanism_AIFM.pdf}. For background, see \url{http://www.who.int/phi/publications/gspa-phi/en/index.html}.
\textsuperscript{58} The project assessment criteria are available at: \url{http://www.who.int/phi/implementation/AssessmentCriteria.pdf}.
\textsuperscript{59} The list of shortlisted regional proposals is available at: \url{http://www.who.int/phi/implementation/phi_cewg_meeting/en/index2.html}.
\textsuperscript{60} Available at: \url{http://www.who.int/phi/implementation/antibiotics_innovation_funding_mechanism_AIFM.pdf}.
\textsuperscript{61} Available at: \url{http://www.who.int/phi/implementation/building_diagnostic_innovation_platform_address_antibiotic_resistance.pdf}.
\textsuperscript{62} Available at: \url{http://www.who.int/phi/implementation/establishing_drug_discovery_platform_antibiotics_public_goods.pdf}.
\textsuperscript{63} Available at: \url{http://www.who.int/phi/implementation/multiplexed_POC_test_acute_febrile_illness.pdf}. 
Two of these projects are discussed below as full antibiotic delinkage models (AIFM and Public Goods). The other two are classified as hybrid models because their delinkage mechanisms are limited to diagnostics. The WHO chose the fourth project for further evaluation.

Nine antibiotic delinkage models will be discussed below:

- **Payer Licenses**
- **Rewarding Antibiotic Development and Responsible Stewardship (RADARS)**
- **GlaxoSmithKline**
- **Patent Buy-out Prize Funds**
- **Strategic Antibiotic Reserve (SAR)**
- **Antibiotic Health Impact Fund (aHIF)**
- **Antibiotic Innovation Funding Mechanism (AIFM)**
- **A Drug Discovery Platform for Sourcing Novel Classes of Antibiotics as Public Goods (Public Goods)**
- **Delinkage Plus**

**Payer Licenses** delink by contracts between the drug company and all of the relevant private and public payers. Instead of reimbursing based on unit prices and unit volumes, the payer license would negotiate an upfront global (or capitated) payment for an antibiotic or an array of antibiotics owned by the company. The antibiotics would then be distributed without further unit payments. Many contracts would be required, with some payers receiving better terms than others. In addition, a clear mechanism to prevent overuse will be required, as each marginal unit is free to the user. Finally, in order to constitute an incentive to commit R&D funds, payer licenses will need to be in place many years before the drugs are used. This seems highly unlikely, but payer licenses could still play a role to support the appropriate use of new drugs without a linkage to sales.

**Rewarding Antibiotic Development and Responsible Stewardship (RADARS).** Some proposals come exceedingly close to delinkage without fully removing all sales revenue. A prominent example is the **RADARS Program** proposed by Rempex Pharmaceuticals, with the following features:

- Public and private payers will reimburse hospitals for the incremental costs of qualified infectious disease products (as defined in the GAIN Act) above and beyond existing DRGs, similar to the Medicare New Technology Ad-on Payment (NTAP) program; payments would only be made if drugs are prescribed in accordance with a preapproved stewardship program.
- Decoupling the use of these antibiotics from traditional pharmaceutical marketing programs by providing:
  - Guaranteed minimum payments for a period of 5 years to the innovator pharmaceutical company irrespective of the volume sold that will guarantee

---

64 From presentations at BCADD and personal communications, with permission from Rempex Pharmaceuticals.
the innovator an acceptable return on investment; these guaranteed minimums would be reduced by the gross profit from units actually sold; these payments should total approximately US$1.2 billion over five years;

- Strict prohibition on the innovator company from promoting the antibiotic through its sales force during this 5 year period as a means of helping stewardship; medical science liaisons could provide product information and formulary kits only;
- After 5 years the guaranteed minimum payments would cease but the NTAP-type payments would continue for an additional 5 years to further reward innovators who produce particularly innovative products and/or accurately address the most troubling resistance trends.

It should be noted that an NTAP payment (one element in RADARS) has been approved for fidaxomicin (Dificid), but the NTAP for fidaxomicin is not delinkage. Under the fidaxomicin NTAP, revenues for the company are still entirely dependent on sales volumes, supported by higher prices via NTAP. These higher prices might actually exacerbate the poor economic incentives inherent in linkage, by increasing the rewards from marketing. In order for RADARS to be truly delinked, the amount of the guaranteed minimum payment should be higher than what the company could achieve through aggressive marketing. In other words, the company’s full revenue stream over the period should be entirely delinked from sales volumes. RADARS could also be modified to extend the period beyond 5 years after renegotiation and to vary the value of the payments. Since RADARS is based on a credible promise from governments, companies could commit R&D funds to projects that might qualify. While the discussion of NTAP is U.S.-centric, national and private payers in other countries could make similar payments.

**GlaxoSmithKline** has not proffered a fully detailed delinkage model *per se*, but has floated principles for delinkage:

- Payments to successful developer of novel antibiotics need to be sufficient to attract further investment. Reduction in uncertainty of revenue is key.
- Payments should remove or significantly reduce the incentive for developer to want to sell more volume - this means fixed payments/fees
  - Main payment triggered by successful licence approval (i.e. success-based)
  - Product provided at cost

---


66 From presentations at BCADD and personal communications, with permission from James Anderson, GSK.
• Payments must be predictable and decision process transparent
  o Target pre-specified by public bodies
  o Commitment to payments should be made at Phase 3 start, in order to support investment in clinical phases.
• New products must be made available to patients who need them, wherever they are in the world, so new model needs to account for this
• If payments are linked to additional responsibilities on industry related to conservation, these should be calculated as separate payments. For example, purchasers should contract separately for supporting services such as:
  o Further clinical studies
  o Identifying inappropriate levels of use
  o Educating doctors and encouraging appropriate use

GSK outlines a valuable framework for full delinkage. The drugs are provided at marginal cost to payers (and perhaps lower to consumers at the point of care) with all company profits deriving from a very significant government-funded income stream.

**Patent Buy-out Prize Funds** such as The Prize Fund for HIV/AIDS, a bill introduced by US Senator Sanders (I-VT), S.1138. If adapted to antibiotics, this bill would be a pure antibiotic delinkage approach. The Prize Fund envisions a public buyout of the relevant patents, followed by public distribution of the drugs. Many permutations of antibiotic prize funds and patent buyouts could possibly qualify as delinkage. The size of these prizes would have to be very significant, in the range of US$500 million to more than US$2 billion at first registration of an outstanding drug. These buyouts should be generous in order to incentivize new R&D. Practical considerations include prizes for sequential innovation, counterparty risk, milestone payments, global coordination, and information asymmetries between the companies and the prize fund. Most of these issues are present in all delinkage models.

**The Strategic Antibiotic Reserve (SAR)** targets only exceptionally valuable molecules for which the patent clock is ticking, but the clinical need for the drug is far in the future. The government (or a group of governments) would purchase the patent for a generous price and save it for a rainy day. The SAR could be seen as a global insurance mechanism, holding a key drug or two in reserve should an urgent need arise. The insurance function is an important element in this sector and should be given more prominence.

---

The Antibiotic Health Impact Fund (AHIF) would make significant payments based on the health impact of the antibiotic, including the health impact on future generations through resistance. The companies would not earn any profits from sales volumes since the drugs are sold at marginal cost. Participation is entirely voluntary. The AHIF could also be designed as a patent buy-out mechanism. The AHIF avoids paying for substandard or inappropriate antibiotics and gives companies powerful incentives to use them judiciously to maximize human health. The AHIF is also globally scalable in that it relies primarily on the companies to achieve goals as opposed to regulatory structures in the developing world. The AHIF is one project within the larger Health Impact Fund effort.

The Antibiotic Innovation Funding Mechanism (AIFM). This proposal was one of 24 regional demonstration project proposals evaluated by the WHO in December 2013. The AIFM is a combination of patent buy-outs prize funds (discussed above) and a fee on antibiotic use. The fee is similar to the antibiotic innovation and conservation fee proposed by the IDSA (discussed below). The combination is innovative, providing full delinkage and a sustainable financing mechanism. Knowledge Ecology International (KEI) authored the AIFM proposal.

A Drug Discovery Platform for Sourcing Novel Classes of Antibiotics as Public Goods (Public Goods). ReACT created the Public Goods proposal for the WHO regional demonstration process in December 2013. The proposal is a variant of patent buy-out prize funds with an emphasis on open source R&D into antibiotics derived from natural products. The treatment of continued antibiotic effectiveness as a public good is thoughtful, with application to all potential models.

Delinkage Plus. At the Chatham House Roundtable in October 2013, several participants envisioned a “delinkage plus” variant on the models described above. Under delinkage plus, providers and payers are given additional incentives and held responsible for conservation while the drug companies focus on bringing drugs to market under one of the delinkage models discussed above. These two functions will be coordinated, perhaps through the core delinkage mechanism, but the ultimate responsibility for success will rest with all of the stakeholders as opposed to just the companies.

2. Hybrid Models

Other proposals should be properly characterized as hybrid models that do not fully or exclusively embrace antibiotic delinkage. For example:

---


70 See www.healthimpactfund.org.


72 The AIFM was not among the eight projects chosen in December 2013 for further evaluation.

73 Available at: http://www.who.int/phi/implementation/establishing_drug_discovery_platform_antibiotics_public_goods.pdf.
Pay-for-Performance (P4P) is a quality-based payment, but applied to antibiotics. Companies and hospitals would be eligible for top-up payments or yearend bonuses, paid directly from governments, if they achieve prevention or conservation goals. Many public and private payers have expanded P4P reimbursements in recent years, including a few with a focus on antibiotics or nosocomial infections.

Antibiotic Conservation and Effectiveness (ACE) Proposal.\textsuperscript{74} ACE is an integrated attempt to simultaneously address conservation and new drug R&D without full delinkage. The proposal combines generous P4P reimbursement and variable marketing exclusivities, all conditioned on the companies meeting clear conservation targets. If the company mismanages the drug, reimbursement falls and generic entry is accelerated. On the other hand, a well-managed drug will result in much greater reimbursement and a longer period of exclusivity. One key will be to set aggressive but achievable targets.

Combatting Antimicrobial Resistance: Policy Recommendations to Save Lives.\textsuperscript{75} In 2011, IDSA published an impressively comprehensive set of recommendations for adoption by the US Congress, including antibiotic P4P, an antibiotic innovation and conservation fee (discussed below), and greatly expanded surveillance, infection control, conservation measures, and funding for R&D. These IDSA recommendations do not include delinkage, but are commendable for their broad scope and simultaneous focus on all stages of the problem (see Figure 2).

Antibiotic Innovation and Conservation (AIC) Fee. The IDSA also proposed an Antibiotic Innovation and Conservation (AIC) fee to induce conservation while funding additional conservation and R&D.\textsuperscript{76} The AIC Fee is a particularly interesting conservation and funding measure worthy of separate discussion. A relatively small tax per script could result in a significant and sustainable flow of funds for conservation activities and basic R&D. The AIC Fee could also induce conservation through higher prices, but this effect will be blunted by efforts to ensure access to all with clinical need for antibiotics. The AIC Fee might be differentially applied to agricultural uses as a mechanism to encourage more appropriate use in that sector without resort to outright bans. From an economic perspective, the magnitude of the tax could be modeled to approximate either the negative externalities of antibiotic use or to fund the conservation and replacement costs of antibiotics that are no longer effective.

Conditional Grants. If major government grants were conditioned on company commitments regarding antibiotic conservation, then the companies would have some incentives to conserve, even if revenues came from sales volumes. Concerns include


\textsuperscript{76} In the economics literature, the AIC would be considered a Pigouvian tax to force the internalization of some of the negative externalities from antibiotic use. See, e.g., Vagsholm I, Hoigard S, ‘Antimicrobial Sensitivity – A Natural Resource to be Protected by a Pigouvian Tax?’, \textit{Preventive Veterinary Medicine}, 2010;96:9-18.
whether grantors like NIH, BARDA, and IMI are well suited to negotiate and enforce antibiotic conservation covenants (c.f. the difficult history with NIH march-in rights) and how companies would respond to future conservation commitments. The conditional grants would have to be larger to offset these uncertainties.

**Options Market for Antibiotics (OMAs).** Call options would be sold by drug firms and purchased by payers. Depending on the contract terms, OMAs might function more like insurance, which is an important aspect of antibiotic policy. OMAs could be designed with delinkage features since the option payment and the strike price are not necessarily tied to marginal unit sales.

**Building a Diagnostic Innovation Platform to Address Antibiotic Resistance (Dx Platform).** Dx Platform is one of the 24 shortlisted WHO regional health R&D proposals. It is treated as a hybrid model here because the scope of delinkage is strictly limited to diagnostics. Improved diagnostics are certainly an important component to appropriate use and therefore continued antimicrobial effectiveness.

**Multiplexed Point-of-Care Test for Acute Febrile Illness (AFI Dx).** AFI Dx is one of the eight health R&D proposals selected by WHO for further evaluation. This proposal is limited to a single valuable diagnostic. This is a valuable project with many benefits, but it is not a comprehensive antibiotic delinkage model.

### 3. Models That Are Not Delinkage

Delinkage requires a clean break from revenues based on sales volumes. Push and pull incentives that are not delinkage include Advance Market Commitments (AMCs), NTAP, Limited Population Antibacterial Drug (LPAD) approval, tiered regulatory frameworks, fast-tracking, streamlining clinical trials, Priority Review Vouchers (PRVs), tax credits, direct funding of R&D, orphan drug designation, the GAIN Act, the IMI, and Project BioShield.

Each of these ideas could be modified to include delinkage, but that would be a significant change. For example:

**Limited Population Antibacterial Drug – Plus (LPAD Plus).** Modify the existing LPAD proposal to include antibiotic conservation commitments by the company, distribution at

---


79 Available at: [http://www.who.int/phi/implementation/building_diagnostic_innovation_platform_address_antibiotic_resistance.pdf](http://www.who.int/phi/implementation/building_diagnostic_innovation_platform_address_antibiotic_resistance.pdf).

80 Available at: [http://www.who.int/phi/implementation/multiplexed_POC_test_acute_febrile_illness.pdf](http://www.who.int/phi/implementation/multiplexed_POC_test_acute_febrile_illness.pdf).


marginal cost, and a very significant registration prize paid by the government. This new proposal (LPAD Plus) is a significant change from the existing LPAD framework. It would boost antibiotic R&D incentives while simultaneously incentivizing conservation. Other examples are possible, but entail quite significant departures from the existing models.

C. Summary

The delinkage and hybrid models are summarized in Figures 4, 5, and 6, followed by some open questions and a few Frequently Asked Questions (FAQs):

Figure 4. Delinkage Models

<table>
<thead>
<tr>
<th>Model</th>
<th>Description</th>
<th>Advantages</th>
<th>Problems</th>
<th>Patents Owned By</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payer Licenses</td>
<td>Payers buy an annual license to have access to the antibiotic; actual antibiotics are delivered to payer at marginal cost</td>
<td>Full delinkage possible; competitive pricing if multiple payers are in the market; government participation not required</td>
<td>Higher transaction costs (annual contracts required between each payer and each manufacturer); private payers will not want to increase overall antibiotic reimbursement; coordination will be difficult; little incentive for new R&amp;D</td>
<td>Private</td>
</tr>
<tr>
<td>RADARS</td>
<td>Payers top-up the hospital DRG for innovative antibiotic; government pays company significant prizes, reduced by company sales receipts; net effect could be full delinkage if the guaranteed payment is large</td>
<td>Increased certainty for companies (existing reimbursement is retained should the prize fail to materialize); conditions increased reimbursement on effective conservation</td>
<td>Hospital-based and US centric; removes hospital financial incentive for conservation; may increase financial return from inappropriate sales unless guaranteed payment is large</td>
<td>Private</td>
</tr>
<tr>
<td>GSK</td>
<td>Fully delinked; predictable revenue stream</td>
<td>Incentivizes new antibiotic innovation together with appropriate use</td>
<td>Model not fully specified; reluctance to integrate other conservation commitments</td>
<td>Private</td>
</tr>
<tr>
<td>Patent Buy-out Prize Funds</td>
<td>Purchase of national patent rights by a government; actual antibiotics are provided by the government; could also be voluntary, allowing companies to opt-in</td>
<td>Full delinkage; one transaction per molecule per country; government can manage the molecule for long-term public health; sales at marginal cost will boost access for low-income populations</td>
<td>Difficult to negotiate appropriate price; political risk; pollution externalities from molecules not in the system</td>
<td>Public</td>
</tr>
</tbody>
</table>
## Strategic Antibiotic Reserve (SAR)\textsuperscript{84}

For particularly important molecules that are not needed yet, a patent buyout or multi-year licence to keep the drug off the market until needed clinically

Saves very important molecules for a rainy day; will be rarely used; could be viewed as an insurance policy; could be a test case for a more comprehensive regime

Akin to paying farmers not to farm (Conservation Reserve Program); pricing will be large and difficult to negotiate

<table>
<thead>
<tr>
<th>               </th>
<th>               </th>
<th>               </th>
<th>               </th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotic Health Impact Fund (AHIF)\textsuperscript{85}</strong></td>
<td>Governments create a fund that will pay for the actual health impact of the antibiotic including conservation; company participation is entirely voluntary</td>
<td>Pays for human health impact on a global basis; companies retain their patents; AHIF provides a nexus for global coordination; sales at marginal cost will boost access for low-income populations</td>
<td>Requires significant up-front financial commitment; measurement of the relative health impact will have significant financial impact for the companies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>               </th>
<th>               </th>
<th>               </th>
<th>               </th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotic Innovation Funding Mechanism (AIFM)</strong></td>
<td>Combination of patent-buy out prize funds (discussed above) and a fee on antibiotic use (discussed below under AIC Fee) for conservation and R&amp;D; WHO Health R&amp;D Regional Demonstration Proposal</td>
<td>Full delinkage; more sustainable funding mechanism; balanced focus; sales at marginal cost will boost access for low-income populations</td>
<td>Same disadvantages as patent buy-out prize funds and the AIC Fee</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>               </th>
<th>               </th>
<th>               </th>
<th>               </th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Establishing a Drug Discovery Platform for Sourcing Novel Classes of Antibiotics as Public Goods (Public Goods)</strong></td>
<td>WHO Health R&amp;D Regional Demonstration Proposal from ReACT; public funding and buy-outs, with an emphasis on antibiotics derived from natural products</td>
<td>Full delinkage; open-source approach to R&amp;D; sales at marginal cost will boost access for low-income populations</td>
<td>Same disadvantages as patent buy-out prize funds; scientific risk with the emphasis on biodiversity sources for natural products</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>               </th>
<th>               </th>
<th>               </th>
<th>               </th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Delinkage plus</strong></td>
<td>Modify any of the delinkage models to strengthen conservation incentives between providers, payers and consumers</td>
<td>Improves incentives at the provider, payer and consumer levels while retaining the company-level delinkage incentives</td>
<td>Additional complexity; conservation might benefit from the information and human capital controlled by drug companies</td>
</tr>
</tbody>
</table>

---


## Figure 5. Hybrid Models

<table>
<thead>
<tr>
<th>Model</th>
<th>Description</th>
<th>Advantages</th>
<th>Problems</th>
<th>Patents Owned By</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pay for Performance (P4P)</td>
<td>Keeps existing reimbursement system intact; company receives a very significant top-up payment for achieving defined quality goals relating to appropriate use and resistance</td>
<td>Easier startup in various national settings; can be contractual or by statute; extension of existing “pay for performance” initiatives; can directly support hospital infection control; could be a test case for a more comprehensive regime</td>
<td>Not delinkage, but linkage with a quality payment that may fail to address underlying problems; will need to be an order of magnitude larger than existing quality incentives in order to attract new capital to the sector; companies may not want conservation responsibilities</td>
<td>Private</td>
</tr>
<tr>
<td>Antibiotic Conservation and Effectiveness (ACE) Proposals</td>
<td>Combination of P4P reimbursement and variable marketing exclusivities, conditioned on meeting conservation targets</td>
<td>Strong incentives for both conservation and new R&amp;D</td>
<td>Significant increase in payor cost for antibiotics; companies may not want conservation responsibilities; unique IP management issues</td>
<td>Private</td>
</tr>
<tr>
<td>Combatting Antimicrobial Resistance: Policy Recommendations to Save Lives (IDSA)</td>
<td>Comprehensive set of proposals for the U.S. Congress</td>
<td>Collects in one place many of the better policy ideas for the US; appropriate focus on all stages; detailed specifications</td>
<td>Piecemeal adoption could threaten the overall cohesion of the proposals; US-centric, but many elements could translate to other national settings</td>
<td>Private</td>
</tr>
<tr>
<td>Antibiotic Innovation and Conservation (AIC) Fee</td>
<td>Impose a fee on antibiotic use to offset negative externalities, with the proceeds used to fund conservation and R&amp;D for new drugs</td>
<td>Sustainable funding mechanism with a strong conservation element; could be an important funding mechanism for any delinkage model</td>
<td>Essentially a tax; cannot be allowed to hinder access at the point of care to appropriate treatment</td>
<td>Private</td>
</tr>
<tr>
<td>Conditional Grants</td>
<td>Funding provides non-dilutive capital, conditioned on advance agreement to meet conservation goals</td>
<td>Piggybacks conservation on existing government grants (IMI, NIH, BARDA)</td>
<td>Increases company uncertainly about revenue stream unless the financial terms and commitments are clear at time of grant</td>
<td>Private</td>
</tr>
<tr>
<td>Options Market for Antibiotics (OMAs)</td>
<td>Companies sell call options on future antibiotic production</td>
<td>Could provide funds during Phase I and II trials; monetizes some of the insurance functions of antimicrobial availability</td>
<td>Option sellers hold most of the information needed to price the option; contact terms will determine whether it is a delinkage mechanism; option holders will have first claim on scarce supplies</td>
<td>Private</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Limited Population Antibacterial Drug (LPAD)(^{86}) Plus</td>
<td>LPAD with conservation commitments, marginal cost sales and a significant prize</td>
<td>Similar to prize funds</td>
<td>Similar problems to conditional grants and prize funds</td>
<td>Private</td>
</tr>
<tr>
<td>Building a Diagnostic Innovation Platform to Address Antibiotic Resistance (Dx Platform)</td>
<td>WHO Health R&amp;D Demonstration Proposal</td>
<td>Improved diagnostics will reduce the spread of resistance</td>
<td>Delinkage is limited to only the diagnostic platform technologies</td>
<td>Public</td>
</tr>
<tr>
<td>Multiplexed Point-of-Care Test for Acute Febrile Illness (AFI Dx)</td>
<td>WHO Health R&amp;D Demonstration Proposal</td>
<td>Could significantly reduce unnecessary use of antimicrobials and therefore delay resistance; selected for further WHO evaluation in Dec. 2013</td>
<td>Narrow focus does not address the larger issues of the need for a new antibiotics business model</td>
<td>Public</td>
</tr>
</tbody>
</table>

The various models can also be arranged based on the ownership of the intellectual property rights (IPRs):

Figure 6. Intellectual Property Rights (IPRs) Ownership in Antibiotic Delinkage and Hybrid Models

<table>
<thead>
<tr>
<th></th>
<th>Delinkage</th>
<th>Hybrid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private IPR</td>
<td>RADARS; Payer Licenses; GSK; AHIF</td>
<td>P4P; ACE; IDSA; AIC Fee; Conditional Grants; OMAS; LPAD Plus</td>
</tr>
<tr>
<td>Buy-out on behalf of the public</td>
<td>Patent Buy-out Prize Funds; SAR; AIFM; Public Goods</td>
<td>Dx Platform; AFI Dx</td>
</tr>
</tbody>
</table>

For low- and middle-income countries, it might be useful to consider IPRs (including licenses) to be held by an independent stakeholder, like the Medicines Patent Pool.

Additional questions when designing delinkage models include:

- Who is best positioned to change behavior to foster prevention and appropriate use? (i.e. manufacturers, governments, or health care provider organizations?) That is, whom do we need to incentivize? (This is the question raised by delinkage plus models).
- What data do we need to collect?
- How do we measure success?
- How do we coordinate conservation globally?
- How do we ensure global antibiotic access to benefit global health?
- Where are the key research gaps?
- What is the long-term human capital plan in antibiotic research?
- How will complex issues of intellectual property be addressed in light of cross-drug and cross-bug resistance and sequential innovation? For example, if multiple drugs within a class generate cross-resistance, the model might need to include all of those drugs, even when owned by multiple companies or now generic.

**Delinkage FAQs**

1. **Does delinkage require higher prices to consumers?** No – the increased rewards are paid by governments or payers, not consumers. Necessary antibiotics must not be rationed to consumers by price, especially for low-income populations.

2. **Can different countries choose different models?** Yes – if the US and the EU agreed on a coordination plan, delinkage goals could still be met if, for example, the EU pursued a patent buyout or AIFM while the US opted for RADARS or a payer license.

3. **How many countries need to participate to achieve a critical mass?** The US and the EU jointly represent two thirds of the global market for antibiotics. Once the US and the EU have agreed on a coordination plan, positive spillovers are likely to other countries even if they do not join. If particular problems develop, the core US and EU delinkage models could include additional incentives for extra-territorial targets. A major issue would be to come up with agreements with other markets that would secure both conservation and sufficient access.

4. **What about sales of antibiotics in countries that do not require prescriptions?** At first, delinkage models could focus on hospital-based IV antibiotics, which present very significant resistance issues and run the risk of treatment failures in serious or life-threatening bacterial diseases. Global coordination is more plausible in the hospital setting, at least for the initial stages.

---